ASSOCIATION BETWEEN MIR-124-1 RS531564 POLYMORPHISM AND RISK OF CANCER: AN UPDATED META-ANALYSIS OF CASE-CONTROL STUDIES

Abdolkarim Moazeni-Roodi1, Mohammad Hashemi2*

1 Department of Clinical Biochemistry, Iranshahr University of Medical Sciences, Iranshahr, Iran
2 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

* Corresponding author: Mohammad Hashemi, PhD, Professor of Clinical Biochemistry, Dept. of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran, E-mail: mhd.hashemi@gmail.com; hashemim@zaums.ac.ir, Tel: +98 541 3235122

http://dx.doi.org/10.17179/excli2018-1419

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).

ABSTRACT

Many studies examined the association between miR-124-1 rs531564 polymorphism and the risk of some human cancers, but the findings remain controversial. This update meta-analysis aimed to validate the association between rs531564 polymorphism of miR-124-1 and cancer risk. Eligible studies including 6,502 cancer cases and 7,213 controls were documented by searching Web of Science, PubMed, Scopus, and Google scholar databases. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to quantitatively evaluate the association between rs531564 variant and cancer risk. The results indicated that rs531564 variant significantly decreased the risk of cancer in homozygous codominant (OR=0.54, 95% CI=0.43-0.69, p<0.00001, GG vs CC), dominant (OR=0.84, 95% CI=0.72-0.99, p=0.03, CG+GG vs CC), recessive (OR=0.65, 95% CI=0.54-0.78, p<0.00001, GG vs CG+CC), and allele (OR=0.84, 95% CI=0.73-0.96, p=0.008, G vs C) genetic model. Stratified analysis by cancer type revealed that rs531564 variant was associated with gastric cancer, cervical cancer, esophageal squamous cell carcinoma and colorectal cancer risk. In summary, the findings of this meta-analysis support an association between miR-124-1 rs531564 polymorphism and cancer risk. Larger and well-designed studies are required to estimate this association in detail.

Keywords: miR-124-1, rs531564, polymorphism, cancer, meta-analysis

INTRODUCTION

Cancer is one of the main leading cause of morbidity and mortality worldwide (Global Burden of Disease Cancer Collaboration, 2015). In 2016, approximately 17.2 million new cancer cases and 8.9 million deaths occurred worldwide (Global Burden of Disease Cancer Collaboration, 2018). It has been proposed that the complex interaction of various genetic loci and diverse environmental factors play a role in cancer development (Borek, 1993; Lichtenstein et al., 2000). Despite physical disparities, all human populations are 99% genetically identical, and the remaining 1% genetic variations is responsible for human diversity (International HapMap Consortium, 2007; Ryan et al., 2010). Single-nucleotide polymorphisms (SNPs) contribute...
to phenotypic differences both within and among populations (Omran et al., 2014).

MicroRNA (miRNA) are a class of noncoding RNAs consisting of 18–25 nucleotides in length that bind to the 3’ untranslated region (3’UTR) of target mRNAs to regulate gene expression (Ryan et al., 2010). Variations in miRNAs genes, including pri-miRNAs, pre-miRNAs, and mature miRNAs, impact on miRNAs biogenesis, processing, target binding, and expression level of mature miRNAs (Mishra et al., 2008). Preceding studies have shown that miRNAs play a crucial role in various tumor-associated biological processes, including proliferation, metastasis, apoptosis and differentiation (He et al., 2013; Liu et al., 2013; Ge et al., 2016).

In human, miR-124 is encoded by three miRNA genes including MIR124-1 (8p23.1), MIR124-2 (8q12.3), and MIR124-3 (20q13.33). A functional polymorphism rs531564 located in the pri-miRNA region of the miR124-1 gene affect the expression levels of the mature miR-124 (Qi et al., 2012). To date, several epidemiological studies inspected the association between miR-124-1 rs531564 polymorphism and the risk of various cancer including gastric cancer (Zhou et al., 2012; Asgarpour et al., 2017; Singh et al., 2017), cervical cancer (Wu and Zhang, 2014; Xiong et al., 2014; Chuanyin et al., 2017), breast cancer (Ma et al., 2013; Ying et al., 2016; Danesh et al., 2018), renal cell carcinoma (Liang et al., 2017), osteosarcoma (Shi et al., 2016), esophageal squamous cell carcinoma (ESCC) (Yin et al., 2013; Zhang et al., 2014; Wu et al., 2018), colorectal cancer (Gao et al., 2015), but the findings are still controversial. Therefore, we performed an updated meta-analysis to find out the impact of rs531564 polymorphism on cancer risk.

METHODS

Literature search

A comprehensive search in Web of Science, PubMed, Scopus, and Google Scholar databases was conducted for all articles describing an association between miR-124-1 rs531564 polymorphism and cancer risk published up to June 08, 2018. The search strategy was “cancer OR carcinoma, tumor OR neoplasms”, AND “miR-124-1 OR microRNA-124-1 OR miRNA-124-1” AND “polymorphism OR mutation OR variant OR rs531564”. Relevant studies included the meta-analysis if they met the following inclusion criteria: 1) Original case-control studies that evaluated the miR-124-1 polymorphism and cancer risk; 2) studies provided necessary information of the genotype frequencies of miR-124-1 rs531564 variant in both cases and controls. The exclusion criteria were: 1) conference abstract, case reports, reviews, duplication data; 2) insufficient genotype information provided.

Data extraction

The authors independently searched the literatures, extracted the relevant data and finally discussed disagreement. The following data were recorded from each study including the first author’s name, publication year, country, ethnicity of participants, cancer type, genotyping methods of miR-124-1 rs531564 polymorphism, number of genotypes in case-control groups and result of the HWE test (Table 1).

Statistical analysis

Meta-analysis was achieved by Revman 5.3 software (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and STATA 14.1 software (Stata Corporation, College Station, TX, USA). Hardy–Weinberg equilibrium (HWE) for each study was calculated by the χ² test. The association between miR-124-1 rs531564 polymorphism and cancer risk was assessed by pooled odds ratios (ORs) and their 95 % confidence intervals (CIs) for codominant (CG vs CC and GG vs CC), dominant (CG+GG vs CC), recessive (GG vs CG+CC), overdominant (CG vs CC+GG) and the allelic (G vs C) genetic inheritance models. The significance of the pooled OR was as-
Table 1: Characteristics of all studies included in the meta-analysis

| First author | Year | Country | Ethnicity | Cancer type | Source of control | Genotyping Method | Case/control | Cases | Controls | HWE (p) |
|--------------|------|---------|-----------|-------------|-----------------|-------------------|--------------|--------|----------|---------|
| Asgar-pour   | 2017 | Iran    | Asian     | Gastric cancer | HB              | PCR-RFLP         | 45/48        | 15     | 27       | 0.04    |
| Chuan-yin    | 2017 | China   | Asian     | Cervical cancer | HB              | TaqMan           | 609/583      | 17     | 144      | 0.85    |
| Danesh       | 2018 | Iran    | Asian     | Breast cancer  | HB              | PCR-RFLP         | 264/280      | 227    | 37       | 0.88    |
| Gao          | 2015 | China   | Asian     | Colorectal cancer | HB              | Sequencing      | 900/1110     | 693    | 200      | 0.19    |
| Liang        | 2017 | China   | Asian     | Renal cell carcinoma | HB              | PCR-LDR         | 132/145      | 95     | 33       | 0.28    |
| Ma           | 2013 | China   | Asian     | Breast cancer  | HB              | Mass ARRAY      | 182/189      | 126    | 52       | 0.1     |
| Shi          | 2016 | China   | Asian     | Osteosarcoma   | HB              | PCR-LDR         | 174/150      | 143    | 25       | 0.002   |
| Singh        | 2017 | China   | Asian     | Gastric cancer  | HB              | PCR-LDR         | 320/586      | 225    | 90       | 0.29    |
| Wu           | 2014 | China   | Asian     | Cervical cancer | PB              | PCR-LDR         | 158/260      | 134    | 22       | 0.19    |
| Wu           | 2018 | China   | Asian     | ESCC*         | HB              | Mass ARRAY      | 239/227      | 173    | 58       | 0.02    |
| Xiong        | 2014 | China   | Asian     | Cervical cancer | PB              | PCR-LDR         | 107/208      | 91     | 15       | 0.5     |
| Yin          | 2013 | China   | Asian     | ESCC*         | HB              | PCR-LDR         | 611/657      | 454    | 146      | 0.4     |
| Ying         | 2016 | China   | Asian     | Colorectal cancer | PB              | Mass ASSAY      | 1350/1079    | 982    | 338      | 0.94    |
| Zhang        | 2014 | China   | Asian     | ESCC*         | PB              | SNaP-shot       | 1109/1275    | 803    | 295      | 0.55    |
| Zhou         | 2012 | China   | Asian     | Gastric cancer  | HB              | Mass ARRAY      | 302/416      | 208    | 89       | 0.97    |

*ESCC = esophageal squamous cell carcinoma
sessed by the Z-test, and $P<0.05$ was considered to be statistically significant. The choice of using fixed or random effects model was determined by the results of the between-study heterogeneity test, which was measured using the $Q$ test and $I^2$ statistic. If the test result was $I^2 \geq 50\%$ or $P_Q < 0.1$, indicating the presence of heterogeneity, the random effect model was selected; otherwise, the fixed-effects model was used.

Begg’s funnel plot was conducted under all inheritance models to evaluate the publication bias and the asymmetric plots implied potential publication bias. The degree of asymmetry was tested using Egger’s test and $p < 0.05$ was considered significant publication bias.

Sensitivity analysis was performed to evaluate the stability of the studies on the pooled ORs. A single study in the analysis was neglected each time to calculate the outcomes again.

RESULTS

Study characteristics
Totally 15 case-control studies including 6,502 cancer cases and 7,213 controls were included in the meta-analyses. Table 1 shows the characteristics and relevant data of the included studies.

Main analysis results
In the current meta-analysis of 15 eligible studies, the findings support an association between miR-124-1 rs531564 polymorphism and cancer risk. The rs531564 variant significantly decreased the risk of cancer in homozygous codominant ($OR=0.54$, 95% CI=0.43-0.69, $p<0.00001$, GG vs CC), dominant ($OR=0.84$, 95% CI=0.72-0.99, $p=0.03$, CG+GG vs CC), recessive ($OR=0.65$, 95% CI=0.54-0.78, $p=0.00001$, GG vs CG+CC), and allele ($OR=0.84$, 95% CI=0.73-0.96, $p=0.008$, G vs C) inheritance model (Figure 1 and Table 2).

Subgroup analysis by cancer type
Stratified analysis of miR-124-1 rs531564 polymorphism was achieved by cancer type (Table 3). The data implied that rs531564 variant increased the risk of gastric cancer in overdominant ($OR=1.27$, 95% CI=1.02-1.58, $p=0.03$, CG vs GG+CC) inheritance model. The rs531564 variant was associated with significantly decrease in risk of cervical cancer in codominant, dominant, recessive and allele inheritance model (Table 3). Furthermore, the variant significantly decreased the risk of ESCC in recessive and allele models. The rs531564 variant was significantly associated with protection against colorectal in recessive model (Table 3). No significant association was found between rs531564 variant and breast cancer risk.

Heterogeneity and publication bias
Heterogeneity among the findings included in the meta-analysis is shown in Table 2. The data showed heterogeneity existed between studies.

The potential publication bias was estimated using a Begg’s funnel plot and Egger’s test. Neither Begg’s funnel plot nor Egger’s test detected any obvious evidence of publication bias in analyses for all genetic models (Table 2 and Figure 2).

Sensitivity analysis
We executed sensitivity analysis to evaluate the effect of a specific study on the overall estimate. The relevant pooled ORs showed no significant change appeared when each study was ignored, one at a time, from the overall meta-analysis in homozygous codominant, dominant, recessive, and allele models (Figure 3). This indicates that the results of this meta-analysis are relatively stable and reliable.
Figure 1: The forest plot for relationship between miR-124-1 rs531564 polymorphism and cancer susceptibility for CG vs CC (A), GG vs CC (B), GG vs CG+CC (C), GG vs CG vs CC (D), and G vs C (E).
Table 2: The pooled ORs and 95% CIs for the association between miR-124-1 rs531564 polymorphism and cancer susceptibility.

| Genetic model | Test of association | Heterogeneity (I² (%), p) | Egger’s test P-value | Begg’s test P-value |
|---------------|---------------------|---------------------------|----------------------|---------------------|
| OR (95% CI)   | Z                   | p                         | χ²                   | I² (%)              | P          |
| CG vs CC      | 0.88 (0.75-1.03)    | 1.56                      | 0.12                 | 39.56               | 65         | 0.0003 | 0.348 | 0.456 |
| GG vs CC      | 0.54 (0.43-0.69)    | 4.91                      | <0.00001             | 19.87               | 30         | 0.13   | 0.444 | 0.903 |
| CG+GG vs CC   | 0.84 (0.72-0.99)    | 2.13                      | 0.03                 | 43.30               | 68 <0.0001 | 0.366 | 0.347 |
| GG vs CG+CC   | 0.65 (0.54-0.78)    | 4.58                      | <0.00001             | 20.04               | 30         | 0.13   | 0.197 | 0.714 |
| CG vs GG+CC   | 0.93 (0.80-1.07)    | 1.01                      | 0.31                 | 38.23               | 63         | 0.0005 | 0.433 | 0.347 |
| G vs C        | 0.84 (0.73-0.96)    | 2.64                      | 0.008                | 41.96               | 67         | 0.0001 | 0.560 | 0.729 |

Table 3: Stratified analysis of miR-124-1 rs531564 variant on susceptibility to cancer

| Cancer type                  | Genetic model | Test of association | Heterogeneity test |
|------------------------------|---------------|---------------------|--------------------|
|                             | OR (95% CI)   | Z                   | p                  |
| Gastric cancer (n=3)         |               |                     |                    |
| CG vs CC                     | 1.09 (0.93-1.27) | 1.03               | 0.03               |
| GG vs CC                     | 0.89 (0.45-1.75) | 0.34               | 0.74               |
| CG+GG vs CC                  | 1.23 (0.99-1.52) | 1.90              | 0.06               |
| GG vs CG+CC                  | 0.82 (0.41-1.61) | 0.59               | 0.56               |
| CG vs GG+CC                  | 1.27 (1.02-1.58) | 2.14              | 0.03               |
| G vs C                       | 1.15 (0.96-1.39) | 1.50              | 0.13               |
| Cervical cancer (n=3)        |               |                     |                    |
| CG vs CC                     | 0.48 (0.33-0.69) | 3.92              | <0.0001            |
| GG vs CC                     | 0.35 (0.17-0.72) | 2.87              | 0.004              |
| CG+GG vs CC                  | 0.44 (0.31-0.63) | 4.45              | <0.0001            |
| GG vs CG+CC                  | 0.72 (0.56-0.94) | 2.46              | 0.01               |
| CG vs GG+CC                  | 0.69 (0.34-1.39) | 1.04              | 0.30               |
| G vs C                       | 0.64 (0.52-0.78) | 4.48              | <0.00001           |
| ESCC* (n=3)                  |               |                     |                    |
| CG vs CC                     | 0.83 (0.61-1.12) | 1.22              | 0.22               |
| GG vs CC                     | 0.54 (0.35-0.86) | 2.64              | 0.008              |
| CG+GG vs CC                  | 0.87 (0.76-1.00) | 1.96              | 0.05               |
| GG vs CG+CC                  | 0.67 (0.29-1.51) | 0.97              | 0.33               |
| CG vs GG+CC                  | 0.83 (0.60-1.15) | 1.12              | 0.26               |
| G vs C                       | 0.86 (0.76-0.97) | 2.45              | 0.01               |
| Colorectal cancer (n=2)      |               |                     |                    |
| CG vs CC                     | 0.97 (0.64-1.48) | 0.14              | 0.89               |
| GG vs CC                     | 0.50 (0.12-2.07) | 0.96              | 0.34               |
| CG+GG vs CC                  | 0.85 (0.65-1.12) | 1.17              | 0.24               |
| GG vs CG+CC                  | 0.60 (0.39-0.91) | 2.38              | 0.02               |
| CG vs GG+CC                  | 0.90 (0.77-1.06) | 1.27              | 0.21               |
| G vs C                       | 0.84 (0.61-1.14) | 1.11              | 0.26               |
| Breast cancer (n=2)          |               |                     |                    |
| CG vs CC                     | 1.21 (0.86-1.71) | 1.11              | 0.27               |
| GG vs CC                     | 0.51 (0.16-1.60) | 1.16              | 0.25               |
| CG+GG vs CC                  | 1.14 (0.82-1.59) | 0.78              | 0.44               |
| GG vs CG+CC                  | 0.48 (0.16-1.51) | 1.25              | 0.21               |
| CG vs GG+CC                  | 1.23 (0.88-1.73) | 1.20              | 0.23               |
| G vs C                       | 1.05 (0.78-1.42) | 0.34              | 0.73               |

*ESCC = esophageal squamous cell carcinoma
Figure 2: The funnel plot for the test of publication bias. The funnel plot for CG vs CC (A), GG vs CC (B), CG+GG vs CC (C), GG vs CG+CC (D), CG vs CC+GG (E), and G vs C (F).
Figure 3: Sensitivity analyses for studies on miR-124-1 rs531564 polymorphism using different genetic models. Sensitivity analyses for CG vs CC (A), GG vs CC (B), CG+GG vs CC (C), GG vs CG+CC (D)
Figure 3 (cont.): Sensitivity analyses for studies on miR-124-1 rs531564 polymorphism using different genetic models. Sensitivity analyses for CG vs CC+GG (E), and G vs C (F).
DISCUSSION

It has been well known that miRNAs is involved in carcinogenesis as tumor suppressor gene or oncogene (Calin et al., 2004; Ryan et al., 2010). Dysregulation of miRNAs contributes to the initiation and progression of human malignancies (Shen et al., 2015; He et al., 2018; Skjefstad et al., 2018). It has been documented that miR-124 is a tumor suppressor miRNA in many cancers (Jin et al., 2017; Yuan et al., 2017; Cai et al., 2018; Ma et al., 2018).

An increasing number of studies have focused on associations between miR-124-1 rs531564 polymorphism and various cancer susceptibility (Zhou et al., 2012; Ma et al., 2013; Yin et al., 2013; Wu and Zhang, 2014; Xiong et al., 2014; Zhang et al., 2014; Gao et al., 2015; Shi et al., 2016; Ying et al., 2016; Asgarpour et al., 2017; Chuanyin et al., 2017; Liang et al., 2017; Singh et al., 2017; Danesh et al., 2018; Wu et al., 2018), but the findings were inconsistent. We performed an updated meta-analysis of 15 case-control studies to find out the impact of rs531564 polymorphism of miR-124-1 gene on overall cancer risk.

The findings of our meta-analysis showed that the rs531564 polymorphism was significantly associated with protection against cancer in homozygous codominant, dominant, recessive and allele inheritance model. Our findings are in agreement with the results of two meta-analyses regarding the impact of miR-124-1 rs531564 variant on cancer risk (Fang et al., 2015; Li et al., 2015). The meta-analysis performed by Li et al. (2015) enrolled 4 case-control studies and the findings revealed that rs531564 polymorphism significantly reduced cancer risk. The other study conducted by Fang et al. (2015) with 5 case-control studies also showed that the pri-miR1241 rs531564 polymorphism significantly reduced cancer risk.

We performed stratified analysis by cancer type and the findings revealed that the rs531564 variant was significantly associated with gastric cancer, cervical cancer ESCC, colorectal and breast cancer risk.

There are several limitations in our meta-analysis that should be addressed. First, heterogeneity existed between some studies. It can be supposed that the heterogeneity probably derived from difference of ethnicity, source of control, status and cancer type. Second, the languages of the studies were limited to English. Third, we did not evaluate potential gene-environmental interactions due to lack of relevant data across the included studies. Finally, all subjects are of Asian descent, so our meta-analysis was limited to Asian population and lack of other ethnicities.

In conclusion, our meta-analysis proposed that miR-124-1 rs531564 polymorphism may be an important protective factor for cancer in Asians. Additional well designed case-control studies with larger sample sizes are required to validate the findings.

Conflict of interest

The authors have declared that no competing interests exist.

REFERENCES

Asgarpour J, Mehrzad J, Yazdi SAT. MicroRNA binding site polymorphisms are associated with the development of gastric cancer. J Cell Mol Res. 2017;9:73-7.

Borek C. Molecular mechanisms in cancer induction and prevention. Environ Health Perspect. 1993;101 (Suppl 3):237-45.

Cai WL, Huang WD, Li B, Chen TR, Li ZX, Zhao CL, et al. MicroRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. Mol Cancer. 2018;17:9.

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999-3004.

Chuanyin L, Xiaona W, Zhiling Y, Yu Z, Shuyuan L, Jie Y, et al. The association between polymorphisms in microRNA genes and cervical cancer in a Chinese Han population. Oncotarget. 2017;8:87914-27.
Danesh H, Hashemi M, Bizhani F, Hashemi SM, Bahari G. Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population. Gene. 2018;647:73-8.

Fang C, Zeng H, Li A, Xu X, Long X. Association of the pri-miR-124-1 rs531564 polymorphism with cancer risk: A meta-analysis. Mol Clin Oncol. 2015;3:892-6.

Gao XR, Wang HP, Zhang SL, Wang MX, Zhu ZS. Pri-miR-124 rs531564 polymorphism and colorectal cancer risk. Sci Rep. 2015;5:14818.

Ge L, Zheng B, Li M, Niu L, Li Z. MicroRNA-497 suppresses osteosarcoma tumor growth in vitro and in vivo. Oncol Lett. 2016;11:2207-12.

Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505-27.

Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;epub. doi: 10.1001/jamaoncol.2018.2706.

He J, Zhang W, Zhou Q, Zhao T, Song Y, Chai L, et al. Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell Biol. 2013;45:1962-73.

He RQ, Yang X, Lian G, Chen G, Ma J. MicroRNA-124-3p expression and its prospective functional pathways in hepatocellular carcinoma: A quantitative polymerase chain reaction, gene expression omnibus and bioinformatics study. Oncol Lett. 2018;15:5517-32.

International HapMap Consortium, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851-61.

Jin H, Li Q, Cao F, Wang SN, Wang RT, Wang Y, et al. MiR-124 inhibits lung tumorigenesis induced by Kras mutation and NNK. Mol Ther Nucleic Acids. 2017;9:145-54.

Li WJ, Wang Y, Gong Y, Tu C, Feng TB, Qi CJ. MicroRNA-124 rs531564 polymorphism and cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2015;16:7905-9.

Liang G, Liu Q, Sun J, Liu W, Shen W. The rs20541 G>A polymorphism in the interleukin 13 gene is associated with a decreased risk of renal cell carcinoma in a Chinese population. Int J Clin Exp Pathol. 2017;10:708-16.

Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78-85.

Liu Z, Gersbach E, Zhang X, Xu X, Dong R, Lee P, et al. MiR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. Mol Cancer Res. 2013;11:1314-25.

Ma F, Zhang P, Lin D, Yu D, Yuan P, Wang J, et al. There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population. PLoS One. 2013;8:e60195.

Ma J, Weng L, Wang Z, Jia Y, Liu B, Wu S, et al. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis. Exp Cell Res. 2018;366:103-13.

Mishra PJ, Mishra PJ, Banerjee D, Bertino JR. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Cell Cycle. 2008;7:853-8.

Omran M, Hashemi M, Eskandari-Nasab E, Hasani SS, Mashhadi MA, Arbabi F, et al. Hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomark Med. 2014;8:259-67.

Qi L, Hu Y, Zhan Y, Wang J, Wang BB, Xia HF, et al. A SNP site in pri-miR-124 changes mature miR-124 expression but no contribution to Alzheimer's disease in a Mongolian population. Neurosci Lett. 2012;515:1-6.

Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10:389-402.

Shen B, Zhang Y, Yu S, Yuan Y, Zhong Y, Lu J, et al. MicroRNA-339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1. FEBS Lett. 2015;589:3205-11.

Shi ZW, Wang JL, Zhao N, Guan Y, He W. Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma. Cancer Biomark. 2016;17:249-57.
Singh DK, Zhang WB, Xu Y, Yin J, Gu HY, Jiang PC. Hsa-miR-34b/c rs4938723 T>C, pri-miR-124-1 rs531564 C>G, pre-miR-125a rs12975333 G>T and hsa-miR-423 rs6505162 C>A polymorphisms and the risk of gastric cardia adenocarcinoma. Int J Clin Exp Med. 2017;10:14919-26.

Skjefstad K, Johannessen C, Grindstad T, Kilvaer T, Paulsen EE, Pedersen M, et al. A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer. Sci Rep. 2018;8:8549.

Wu F, Li M, You W, Ji Y, Cui X, Hu J, et al. A genetic variant in miR-124 decreased the susceptibility to esophageal squamous cell carcinoma in a Chinese Kazakh population. Genet Test Mol Biomark. 2018;22:29-34.

Wu H, Zhang J. MiR-124 rs531564 polymorphism influences genetic susceptibility to cervical cancer. Int J Clin Exp Med. 2014;7:5847-51.

Xiong X, Cheng J, Liu X, Tang S, Luo X. [Correlation analysis between miR-124 rs531564 polymorphisms and susceptibility to cervical cancer]. Nan Fang Yi Ke Da Xue Xue Bao. 2014;34:210-3.

Yin J, Wang X, Zheng L, Shi Y, Wang L, Shao A, et al. Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS ONE. 2013;8:e80570.

Ying HQ, Peng HX, He BS, Pan YQ, Wang F, Sun HL, et al. MiR-608, pre-miR-124-1 and pre-miR26a-1 polymorphisms modify susceptibility and recurrence-free survival in surgically resected CRC individuals. Oncotarget. 2016;7:75865-73.

Yuan L, Li S, Zhou Q, Wang D, Zou D, Shu J, et al. MiR-124 inhibits invasion and induces apoptosis of ovarian cancer cells by targeting programmed cell death 6. Oncol Lett. 2017;14:7311-7.

Zhang J, Huang X, Xiao J, Yang Y, Zhou Y, Wang X, et al. Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PLoS ONE. 2014;9:e100055.

Zhou Y, Du WD, Chen G, Ruan J, Xu S, Zhou FS, et al. Association analysis of genetic variants in microRNA networks and gastric cancer risk in a Chinese Han population. J Cancer Res Clin Oncol. 2012;138:939-45.